Dalbavancin vs standard antibiotics for catheter bloodstream infection
Part of Infections clinical trials.
This trial tests whether dalbavancin (an antibiotic given as a dose or doses) works as well as standard antibiotics to treat bloodstream infections related to a removed IV catheter caused by Staphylococcus aureus. It may help reduce treatment time and dosing complexity if you qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your blood cultures show Staphylococcus aureus, and the sample was taken within 72 hours before randomization
- You have a catheter-related bloodstream infection (likely tied to your catheter), and any involved catheter was removed before the study starts
- The infection is caused by one type of Staphylococcus aureus (not multiple germs), and the bacteria are not dalbavancin-resistant
- You have received no more than 72 hours of effective antibiotic treatment aimed at Staphylococcus aureus before randomization
- You can sign the informed consent form yourself
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if the antibiotic dalbavancin can effectively treat a certain type of serious heart valve infection (endocarditis) caused by specific bacteria. You may be eligible if you have this infection in your left-sided heart valves and are at least 18 years old.
This trial tests whether switching from IV antibiotics to oral antibiotics after 3–7 days is safe and effective for people with uncomplicated Staphylococcus aureus bloodstream infections. It may help you avoid a longer hospital stay and reduce IV-related complications.
This study looks back at patients who received the antibiotic dalbavancin as a long-term suppressive therapy for stubborn infections. It aims to see how well it worked and if it was safe.
This trial tests a combination of antibiotics (BV100, polymyxin B, and either ceftazidime/avibactam or cefiderocol) for serious lung or bloodstream infections caused by a tough-to-treat bacteria called Acinetobacter. The goal is to see if the combination is safe and works better than current treatments.
This trial tests if an antibiotic called dalbavancin can help prevent serious bacterial infections in children and young adults with high-risk leukemia whose immune systems are weakened by treatment.
This study tests a new approach to prevent infections on central venous catheters (thin tubes inserted into large veins) in hospital intensive care units. Researchers will study catheters that already show signs of bacterial growth to understand how to better protect patients from catheter-related infections.
Hear when a new Staphylococcus Aureus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.